Viscosity-Lowering Effect of Amino Acids and Salts on Highly Concentrated Solutions of Two IgG1 Monoclonal Antibodies

Molecular Pharmaceutics

Volumn 12, Issue 12, 2015, Pages 4478-4487

  Wang, Shujing ^a   Zhang, Ning ^b   Hu, Tao ^b   Dai, Weiguo ^b   Feng, Xiuying ^b   Zhang, Xinyi ^a   Qian, Feng ^a  

^a TSINGHUA UNIVERSITY   (China)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

amino acids; mAb stability; monoclonal antibody; protein protein interaction; subcutaneous injection; viscosity

Indexed keywords

ALANINE; AMINO ACID; AMMONIA; ARGININE; GLUTAMATE SODIUM; GLYCINE; GUANIDINE; HISTIDINE; IMMUNOGLOBULIN G1 ANTIBODY; INORGANIC SALT; LYSINE; MONOCLONAL ANTIBODY; PROLINE; SERINE; SODIUM CHLORIDE; UREA; VALINE; EXCIPIENT; IMMUNOGLOBULIN G; SOLUTION AND SOLUBILITY;

ARTICLE; CONFORMATIONAL TRANSITION; HYDRODYNAMICS; MOLECULAR STABILITY; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; TRANSITION TEMPERATURE; VISCOSITY; ZETA POTENTIAL; CHEMISTRY; MEDICINAL CHEMISTRY; PROCEDURES; SOLUTION AND SOLUBILITY;

AMINO ACIDS; ANTIBODIES, MONOCLONAL; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; IMMUNOGLOBULIN G; PHARMACEUTICAL SOLUTIONS; SALTS; VISCOSITY;

EID: 84949008876     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00643     Document Type: Article

References (54)

1. Nelson, A. L.; Dhimolea, E.; Reichert, J. M. Development trends for human monoclonal antibody therapeutics Nat. Rev. Drug Discovery 2010, 9 (10) 767-74 10.1038/nrd3229
2. An, Z. Monoclonal antibodies-a proven and rapidly expanding therapeutic modality for human diseases Protein Cell 2010, 1 (4) 319-30 10.1007/s13238-010-0052-8
3. Weiner, G. J. Building better monoclonal antibody-based therapeutics Nat. Rev. Cancer 2015, 15 (6) 361-70 10.1038/nrc3930
4. Mitragotri, S.; Burke, P. A.; Langer, R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies Nat. Rev. Drug Discovery 2014, 13 (9) 655-72 10.1038/nrd4363
5. Dani, B.; Platz, R.; Tzannis, S. T. High concentration formulation feasibility of human immunoglubulin G for subcutaneous administration J. Pharm. Sci. 2007, 96 (6) 1504-17 10.1002/jps.20508
6. Misbah, S.; Sturzenegger, M. H.; Borte, M.; Shapiro, R. S.; Wasserman, R. L.; Berger, M.; Ochs, H. D. Subcutaneous immunoglobulin: opportunities and outlook Clin. Exp. Immunol. 2009, 158 (Suppl s1) 51-59 10.1111/j.1365-2249.2009.04027.x
7. Sanford, M. Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer Target Oncol 2014, 9 (1) 85-94 10.1007/s11523-014-0313-1
8. Nakashima, Y.; Kondo, M.; Miyahara, H.; Iwamoto, Y. Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis-focus on subcutaneous tocilizumab Drug Des., Dev. Ther. 2014, 8, 913-9 10.2147/DDDT.S52099
9. Binabaji, E.; Ma, J.; Zydney, A. L. Intermolecular Interactions and the Viscosity of Highly Concentrated Monoclonal Antibody Solutions Pharm. Res. 2015, 32, 3102 10.1007/s11095-015-1690-6
10. Sule, S. V.; Cheung, J. K.; Antochshuk, V.; Bhalla, A. S.; Narasimhan, C.; Blaisdell, S.; Shameem, M.; Tessier, P. M. Solution pH That Minimizes Self-Association of Three Monoclonal Antibodies Is Strongly Dependent on Ionic Strength Mol. Pharmaceutics 2012, 9 (4) 744-751 10.1021/mp200448j
11. Frokjaer, S.; Otzen, D. E. Protein drug stability: a formulation challenge Nat. Rev. Drug Discovery 2005, 4 (4) 298-306 10.1038/nrd1695
12. Manning, M. C.; Chou, D. K.; Murphy, B. M.; Payne, R. W.; Katayama, D. S. Stability of protein pharmaceuticals: an update Pharm. Res. 2010, 27 (4) 544-75 10.1007/s11095-009-0045-6
13. Kamerzell, T. J.; Esfandiary, R.; Joshi, S. B.; Middaugh, C. R.; Volkin, D. B. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development Adv. Drug Delivery Rev. 2011, 63 (13) 1118-59 10.1016/j.addr.2011.07.006
14. Zhang, L.; Zhang, J. Specific ion-protein interactions dictate solubility behavior of a monoclonal antibody at low salt concentrations Mol. Pharmaceutics 2012, 9 (9) 2582-90 10.1021/mp300183a
15. Brader, M. L.; Estey, T.; Bai, S.; Alston, R. W.; Lucas, K. K.; Lantz, S.; Landsman, P.; Maloney, K. M. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies Mol. Pharmaceutics 2015, 12 (4) 1005-17 10.1021/mp400666b
16. Mueller, M.; Loh, M. Q.; Tscheliessnig, R.; Tee, D. H.; Tan, E.; Bardor, M.; Jungbauer, A. Liquid formulations for stabilizing IgMs during physical stress and long-term storage Pharm. Res. 2013, 30 (3) 735-50 10.1007/s11095-012-0914-2
17. He, F.; Woods, C. E.; Trilisky, E.; Bower, K. M.; Litowski, J. R.; Kerwin, B. A.; Becker, G. W.; Narhi, L. O.; Razinkov, V. I. Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis J. Pharm. Sci. 2011, 100 (4) 1330-40 10.1002/jps.22384
18. Lilyestrom, W. G.; Shire, S. J.; Scherer, T. M. Influence of the cosolute environment on IgG solution structure analyzed by small-angle X-ray scattering J. Phys. Chem. B 2012, 116 (32) 9611-8 10.1021/jp303839t
19. Manikwar, P.; Majumdar, R.; Hickey, J. M.; Thakkar, S. V.; Samra, H. S.; Sathish, H. A.; Bishop, S. M.; Middaugh, C. R.; Weis, D. D.; Volkin, D. B. Correlating excipient effects on conformational and storage stability of an IgG1 monoclonal antibody with local dynamics as measured by hydrogen/deuterium-exchange mass spectrometry J. Pharm. Sci. 2013, 102 (7) 2136-51 10.1002/jps.23543
20. Park, J.; Nagapudi, K.; Vergara, C.; Ramachander, R.; Laurence, J. S.; Krishnan, S. Effect of pH and excipients on structure, dynamics, and long-term stability of a model IgG1 monoclonal antibody upon freeze-drying Pharm. Res. 2013, 30 (4) 968-84 10.1007/s11095-012-0933-z
21. Kheddo, P.; Tracka, M.; Armer, J.; Dearman, R. J.; Uddin, S.; van der Walle, C. F.; Golovanov, A. P. The effect of arginine glutamate on the stability of monoclonal antibodies in solution Int. J. Pharm. 2014, 473 (1-2) 126-33 10.1016/j.ijpharm.2014.06.053
22. Rizzo, J. M.; Shi, S.; Li, Y.; Semple, A.; Esposito, J. J.; Yu, S.; Richardson, D.; Antochshuk, V.; Shameem, M. Application of a high-throughput relative chemical stability assay to screen therapeutic protein formulations by assessment of conformational stability and correlation to aggregation propensity J. Pharm. Sci. 2015, 104 (5) 1632-40 10.1002/jps.24408
23. Guo, Z.; Chen, A.; Nassar, R. A.; Helk, B.; Mueller, C.; Tang, Y.; Gupta, K.; Klibanov, A. M. Structure-activity relationship for hydrophobic salts as viscosity-lowering excipients for concentrated solutions of monoclonal antibodies Pharm. Res. 2012, 29 (11) 3102-9 10.1007/s11095-012-0802-9
24. Singh, S. N.; Yadav, S.; Shire, S. J.; Kalonia, D. S. Dipole-dipole interaction in antibody solutions: correlation with viscosity behavior at high concentration Pharm. Res. 2014, 31 (9) 2549-58 10.1007/s11095-014-1352-0
25. Yadav, S.; Laue, T. M.; Kalonia, D. S.; Singh, S. N.; Shire, S. J. The influence of charge distribution on self-association and viscosity behavior of monoclonal antibody solutions Mol. Pharmaceutics 2012, 9 (4) 791-802 10.1021/mp200566k
26. Scherer, T. M.; Liu, J.; Shire, S. J.; Minton, A. P. Intermolecular interactions of IgG1 monoclonal antibodies at high concentrations characterized by light scattering J. Phys. Chem. B 2010, 114 (40) 12948-57 10.1021/jp1028646
27. He, F.; Woods, C. E.; Litowski, J. R.; Roschen, L. A.; Gadgil, H. S.; Razinkov, V. I.; Kerwin, B. A. Effect of sugar molecules on the viscosity of high concentration monoclonal antibody solutions Pharm. Res. 2011, 28 (7) 1552-60 10.1007/s11095-011-0388-7
28. Hirano, A.; Arakawa, T.; Shiraki, K. Arginine increases the solubility of coumarin: comparison with salting-in and salting-out additives J. Biochem. 2008, 144 (3) 363-9 10.1093/jb/mvn078
29. Shiraki, K.; Kudou, M.; Fujiwara, S.; Imanaka, T.; Takagi, M. Biophysical effect of amino acids on the prevention of protein aggregation J. Biochem. 2002, 132 (4) 591-5 10.1093/oxfordjournals.jbchem.a003261
30. Szenczi, A.; Kardos, J.; Medgyesi, G. A.; Zavodszky, P. The effect of solvent environment on the conformation and stability of human polyclonal IgG in solution Biologicals 2006, 34 (1) 5-14 10.1016/j.biologicals.2005.06.007
31. Inoue, N.; Takai, E.; Arakawa, T.; Shiraki, K. Arginine and lysine reduce the high viscosity of serum albumin solutions for pharmaceutical injection J. Biosci Bioeng 2014, 117 (5) 539-43 10.1016/j.jbiosc.2013.10.016
32. Inoue, N.; Takai, E.; Arakawa, T.; Shiraki, K. Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations Mol. Pharmaceutics 2014, 11 (6) 1889-96 10.1021/mp5000218
33. Bolli, R.; Woodtli, K.; Bartschi, M.; Hofferer, L.; Lerch, P. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions Biologicals 2010, 38 (1) 150-7 10.1016/j.biologicals.2009.09.002
34. Sharma, V.; Jaishankar, A.; Wang, Y.; McKinley, G. Rheology of globular proteins: apparent yield stress, high shear rate viscosity and interfacial viscoelasticity of bovine albumin solutions Soft Matter 2011, 7 (11) 5150-5160 10.1039/c0sm01312a
35. Burckbuchler, V.; Mekhloufi, G.; Giteau, A. P.; Grossiord, J. L.; Huille, S.; Agnely, F. Rheological and syringeability properties of highly concentrated human polyclonal immunoglobulin solutions Eur. J. Pharm. Biopharm. 2010, 76 (3) 351-6 10.1016/j.ejpb.2010.08.002
36. Allmendinger, A.; Fischer, S.; Huwyler, J.; Mahler, H. C.; Schwarb, E.; Zarraga, I. E.; Mueller, R. Rheological characterization and injection forces of concentrated protein formulations: an alternative predictive model for non-Newtonian solutions Eur. J. Pharm. Biopharm. 2014, 87 (2) 318-28 10.1016/j.ejpb.2014.01.009
37. Liu, J.; Nguyen, M. D.; Andya, J. D.; Shire, S. J. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution J. Pharm. Sci. 2005, 94 (9) 1928-40 10.1002/jps.20347
38. Connolly, B. D.; Petry, C.; Yadav, S.; Demeule, B.; Ciaccio, N.; Moore, J. M. R.; Shire, S. J.; Gokarn, Y. R. Weak Interactions Govern the Viscosity of Concentrated Antibody Solutions: High-Throughput Analysis Using the Diffusion Interaction Parameter Biophys. J. 2012, 103 (1) 69-78 10.1016/j.bpj.2012.04.047
39. Arakawa, T.; Timasheff, S. N. Preferential interactions of proteins with salts in concentrated solutions Biochemistry 1982, 21 (25) 6545-52 10.1021/bi00268a034
40. Arakawa, T.; Ejima, D.; Tsumoto, K.; Obeyama, N.; Tanaka, Y.; Kita, Y.; Timasheff, S. N. Suppression of protein interactions by arginine: a proposed mechanism of the arginine effects Biophys. Chem. 2007, 127 (1-2) 1-8 10.1016/j.bpc.2006.12.007
41. Arakawa, T.; Timasheff, S. N. Abnormal solubility behavior of beta-lactoglobulin: salting-in by glycine and NaCl Biochemistry 1987, 26 (16) 5147-53 10.1021/bi00390a038
42. Yadav, S.; Shire, S. J.; Kalonia, D. S. Viscosity analysis of high concentration bovine serum albumin aqueous solutions Pharm. Res. 2011, 28 (8) 1973-83 10.1007/s11095-011-0424-7
43. Kanai, S.; Liu, J.; Patapoff, T. W.; Shire, S. J. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity J. Pharm. Sci. 2008, 97 (10) 4219-27 10.1002/jps.21322
44. Teale, F. W. The ultraviolet fluorescence of proteins in neutral solution Biochem. J. 1960, 76, 381-8 10.1042/bj0760381
45. Vazquez-Rey, M.; Lang, D. A. Aggregates in monoclonal antibody manufacturing processes Biotechnol. Bioeng. 2011, 108 (7) 1494-508 10.1002/bit.23155
46. Ratanji, K. D.; Derrick, J. P.; Dearman, R. J.; Kimber, I. Immunogenicity of therapeutic proteins: influence of aggregation J. Immunotoxicol. 2014, 11 (2) 99-109 10.3109/1547691X.2013.821564
47. Maeder, W.; Lieby, P.; Sebald, A.; Spycher, M.; Pedrussio, R.; Bolli, R. Local tolerance and stability up to 24 months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration Biologicals 2011, 39 (1) 43-9 10.1016/j.biologicals.2010.11.004
48. Chennamsetty, N.; Voynov, V.; Kayser, V.; Helk, B.; Trout, B. L. Design of therapeutic proteins with enhanced stability Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (29) 11937-42 10.1073/pnas.0904191106
49. Ionescu, R. M.; Vlasak, J.; Price, C.; Kirchmeier, M. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies J. Pharm. Sci. 2008, 97 (4) 1414-26 10.1002/jps.21104
50. Vermeer, A. W.; Norde, W. The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein Biophys. J. 2000, 78 (1) 394-404 10.1016/S0006-3495(00)76602-1
51. Ablinger, E.; Hellweger, M.; Leitgeb, S.; Zimmer, A. Evaluating the effects of buffer conditions and extremolytes on thermostability of granulocyte colony-stimulating factor using high-throughput screening combined with design of experiments Int. J. Pharm. 2012, 436 (1-2) 744-52 10.1016/j.ijpharm.2012.07.046
52. Zhang-van Enk, J.; Mason, B. D.; Yu, L.; Zhang, L.; Hamouda, W.; Huang, G.; Liu, D.; Remmele, R. L., Jr.; Zhang, J. Perturbation of thermal unfolding and aggregation of human IgG1 Fc fragment by Hofmeister anions Mol. Pharmaceutics 2013, 10 (2) 619-30 10.1021/mp300378y
53. Yang, H. Y.; Yang, S. N.; Kong, J. L.; Dong, A. C.; Yu, S. N. Obtaining information about protein secondary structures in aqueous solution using Fourier transform IR spectroscopy Nat. Protoc. 2015, 10 (3) 382 10.1038/nprot.2015.024
54. Bandekar, J. Amide modes and protein conformation Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol. 1992, 1120 (2) 123-43 10.1016/0167-4838(92)90261-B